WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
09 January 2020 - 11:25PM
WPD Pharmaceuticals (CSE: WBIO) (the “
Company” or
“
WPD”), a clinical stage pharmaceutical company,
is pleased to announce that on December 31, 2019, Wake Forest
University received a patent from the United States Patent and
Trademark Office (“
USPTO”) for patent 105019210
(issued under application number 16/262,195v) licensed to WPD. The
patent is in respect to a protein critical in the development of
Th2 immune responses, which are associated with allergy, asthma,
fibrosis and aggressive forms of cancer.
IL-13 proteins were shown to be important
factors in eliminating tumor cells related to various forms of
cancer. Recombinant IL-13 protein armed with potent bacteria toxins
preferentially bind to tumor-specific receptors and
selectively deliver highly cytotoxic payload to tumor cells. This
highly specific targeting of aggressive brain tumor
glioblastoma (GBM) and other tumor cells is designed to allow for
selective elimination of tumor cells by
bacteria-toxins-induced cytotoxic effects without affecting normal
cells. IL-13 protein can also assist in the survival and the
development of tumor-associated immune cells, which could be
beneficial for individuals with autoimmune diseases and forms of
cancer associated with Th2 immune responses.
Mariusz Olejniczak, CEO of WPD
commented, “WPD continues to develop its robust
drug portfolio and the patent granted for our cancer
targeting IL-13 proteins strongly protects our IP as
we advance development of our brain cancer focused therapeutic
program. We will continue to work closely with Wake Forest
University on the IL-13 and Ephrine technology platforms to
rapidly advance our current pre-clinical studies.”
About WPD Pharmaceuticals
WPD is a biotechnology research and development
company with a focus on oncology, namely research and development
of medicinal products involving biological compounds and small
molecules. WPD has 8 novel drug candidates with 4 that are in
clinical development stage and 4 in pre-clinical development. These
drug candidates were researched at institutions including MD
Anderson Cancer Center, Mayo Clinic and Emory University, and WPD
currently has ongoing collaborations with Wake Forest University
and leading hospitals and academic centers in Poland.
WPD has entered into license agreements with
Wake Forest University Health Sciences and sublicense agreements
with Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc.,
respectively, each of which grant WPD an exclusive, royalty-bearing
sublicense to certain technologies of the licensor. Such agreements
provide WPD with certain research, development, manufacturing and
sales rights, among other things.
On Behalf of the Board
‘Mariusz Olejniczak’
Mariusz OlejniczakCEO, WDP Pharmaceuticals
Contact:
Investor RelationsEmail:
investors@wpdpharmaceuticals.comTel: 604-428-7050Web:
www.wpdpharmaceuticals.com
Cautionary Statements:
Investors are cautioned that, except as
disclosed in the Company’s CSE listing statement, prepared in
accordance with the policies of the CSE, any information released
or received with respect to the transaction may not be accurate or
complete and should not be relied upon. Trading in the securities
of the Company should be considered highly speculative.
Neither the Canadian Securities Exchange nor the
Investment Industry Regulatory Organization of Canada accepts
responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking
statements. Forward-looking statements are statements that
contemplate activities, events or developments that the Company
anticipates will or may occur in the future. Forward-looking
statements in this press release include those regarding the
Company’s plan to continue to work closely with Wake Forest
University on the IB-13 and Ephrine technology platforms.
These forward-looking statements reflect the Company’s current
expectations based on information currently available to management
and are subject to a number of risks and uncertainties that may
cause outcomes to differ materially from those projected.
Readers should refer to the risk disclosure included from
time-to-time in the documents the Company files on SEDAR, available
at www.sedar.com. Although the Company believes that the
assumptions inherent in these forward-looking statements are
reasonable, they are not guarantees of future performance and,
accordingly, they should not be relied upon and there can be no
assurance that any of them will prove to be accurate.
Finally, these forward-looking statements are made as of the date
of this press release and the Company assumes no obligation to
update them except as required by applicable law.
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
WPD Pharmaceuticals (CSE:WBIO)
Historical Stock Chart
From Jul 2023 to Jul 2024